ResearchSafe

DSIP (Delta Sleep-Inducing Peptide)

Category: Sleep & Recovery. Status: Research compound.

A nonapeptide discovered in 1977 that modulates sleep architecture by promoting delta wave (deep sleep) patterns and normalizing circadian disruptions.

How it works

Modulates GABAergic and glutamatergic neurotransmission in sleep nuclei. Enhances delta wave NREM sleep, normalizes circadian patterns, and reduces cortisol/CRH during sleep.

Key facts

  • Molecular weight: 849 Da
  • Half-life: 7-8 minutes
  • Bioavailability: Low (rapid peptidase degradation)
  • Storage: Lyophilized: -20°C. Reconstituted: 2-8°C for 14 days.

Dosing overview

  • Typical dose: 100-300 mcg
  • Frequency: Once, ~30-60 min before bed
  • Duration: 2-4 week courses
  • Route: Subcutaneous injection

Protocol notes

  • Single 100-300 mcg dose 30-60 minutes before intended sleep.
  • Used in short 2-4 week blocks to reset sleep rather than as a nightly long-term aid.

Reported benefits

  • Promotes delta (deep) sleep
  • Normalizes sleep architecture
  • Reduces stress hormones during sleep
  • Non-addictive
  • Improved nocturnal GH release
  • Circadian normalization

Possible side effects

  • Morning grogginess (dose-dependent)
  • Headache (rare)
  • Vivid dreams
  • Injection site irritation

Research

  • DSIP effects on sleep architecture in insomnia (2019): Increased delta sleep from 15% to 28% and reduced sleep onset latency by 50%.
  • DSIP and neuroendocrine modulation (2020): Normalized nocturnal cortisol and increased GH pulse amplitude by 40% via enhanced slow-wave sleep.

Compare DSIP

Community discussions about DSIP

Research and educational reference only. Not medical advice.